{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:18:23Z","timestamp":1787653103308,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01361-0","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T11:42:56Z","timestamp":1767526976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4\u2013targeting PET tracer [\u2076\u2078Ga]Ga-FZ-NR-1 in humans"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6472-9324","authenticated-orcid":false,"given":"Xiaoqiang","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"1361_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrm2457","volume":"9","author":"Y Takai","year":"2008","unstructured":"Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact Inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9:603\u201315. https:\/\/doi.org\/10.1038\/nrm2457","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1361_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/annonc\/mdw678","volume":"28","author":"M M-Rabet","year":"2017","unstructured":"M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017;28:769\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdw678","journal-title":"Ann Oncol"},{"key":"1361_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting Nectin-4 in urothelial carcinoma. Nat Reviews Urol. 2021;18:93\u20131039. https:\/\/doi.org\/10.1038\/s41585-020-00394-5","journal-title":"Nat Reviews Urol"},{"key":"1361_CR4","doi-asserted-by":"publisher","first-page":"174516","DOI":"10.1016\/j.ejphar.2021.174516","volume":"911","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (Nectin-4): a potential target for cancer therapy. Eur J Pharmacol. 2021;911:174516. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174516","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1361_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3892\/ijmm.2025.5507","volume":"55","author":"R Fu","year":"2025","unstructured":"Fu R, Wang C, Yin T, Zhang X, Xu Y, Shi Y, et al. A novel and promising therapeutic approach for treating pancreatic cancer: Nectin-4-targeted antibody-drug conjugates alone or combined with autophagy inhibitors[J]. Int J Mol Med. 2025;55(4):66. https:\/\/doi.org\/10.3892\/ijmm.2025.5507","journal-title":"Int J Mol Med"},{"key":"1361_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncponc1041","volume":"5","author":"WA Weber","year":"2008","unstructured":"Weber WA, Grosu AL, Czernin J. Technology insight: advances in molecular imaging and an appraisal of PET\/CT scanning. Nat Clin Pract Oncol. 2008;5:160\u201370. https:\/\/doi.org\/10.1038\/ncponc1041","journal-title":"Nat Clin Pract Oncol"},{"key":"1361_CR7","doi-asserted-by":"publisher","first-page":"20030","DOI":"10.1038\/s41598-024-70380-z","volume":"14","author":"L Frings","year":"2024","unstructured":"Frings L, Blazhenets G, Brumberg J, Rau A, Urbach H, Meyer PT. Deformationbased morphometry applied to FDG PET data reveals hippocampal atrophy in alzheimer\u2019s disease. Sci Rep. 2024;14:20030. https:\/\/doi.org\/10.1038\/s41598-024-70380-z","journal-title":"Sci Rep"},{"key":"1361_CR8","doi-asserted-by":"publisher","unstructured":"Liu Y, Huang W, Zhou J, Saladin RJ, Y Lei, Cai W, et al. Nectin4-targeted molecular imaging in solid tumors: Current status and future perspectives. View (2025): 20250007. https:\/\/doi.org\/10.1002\/VIW.20250007}","DOI":"10.1002\/VIW.20250007"},{"issue":"4","key":"1361_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40291-025-00786-6","volume":"29","author":"G Speltri","year":"2025","unstructured":"Speltri G, Badrane I, Napolitano R, Boschi A, Uccelli L, Filippi L, et al. Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer: G. Speltri et al. Molecular Diagnosis & Therapy 29.4 (2025): 453-463.Speltri G, Badrane I, Napolitano R, Speltri, et al. Mol Diagn Ther. 2025;29(4):453\u201363. https:\/\/doi.org\/10.1007\/s40291-025-00786-6","journal-title":"Mol Diagn Ther"},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41416-024-02779-4","volume":"131","author":"R Wang","year":"2024","unstructured":"Wang R, Liu S, Chen B, Li Q, Cheng X, Zhu Y, et al. Prognostic significance of PET\/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study. Br J Cancer. 2024;131:709\u201317. https:\/\/doi.org\/10.1038\/s41416-024-02779-4","journal-title":"Br J Cancer"},{"key":"1361_CR11","doi-asserted-by":"publisher","first-page":"916693","DOI":"10.3389\/fmed.2022.916693","volume":"9","author":"R Manafi-Farid","year":"2022","unstructured":"Manafi-Farid R, Ataeinia B, Ranjbar S, Jamshidi Araghi Z, Moradi MM, Pirich C, et al. ImmunoPET: antibody-based PET imaging in solid tumors. Front Med. 2022;9:916693. https:\/\/doi.org\/10.3389\/fmed.2022.916693","journal-title":"Front Med"},{"key":"1361_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1021\/cbmi.4c00030","volume":"2","author":"M Shabsigh","year":"2024","unstructured":"Shabsigh M, Solomon LA. Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine. Chem Biomedical Imaging. 2024;2:615\u201330. https:\/\/doi.org\/10.1021\/cbmi.4c00030","journal-title":"Chem Biomedical Imaging"},{"issue":"9","key":"1361_CR13","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.molpharmaceut.4c00366","volume":"21","author":"Q Wan","year":"2024","unstructured":"Wan Q, Yuan H, Cai P, Liu Y, Yan T, Wang L, et al. Effects of pegylation on imaging contrast of (68)Ga-Labeled bicyclic peptide PET probes targeting Nectin-4. Mol Pharm. 2024;21(9):4430\u201340. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00366","journal-title":"Mol Pharm"},{"issue":"5","key":"1361_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11307-016-0953-x","volume":"18","author":"DO Campbell","year":"2016","unstructured":"Campbell DO, Noda A, Verlinsky A, Snyder J, Fujita Y, Murakami Y, et al. Preclinical evaluation of an Anti-Nectin-4 ImmunoPET reagent in Tumor-Bearing mice and biodistribution studies in cynomolgus monkeys. Mol Imaging Biology. 2016;18(5):768\u201375. https:\/\/doi.org\/10.1007\/s11307-016-0953-x","journal-title":"Mol Imaging Biology"},{"issue":"21","key":"1361_CR15","doi-asserted-by":"publisher","first-page":"14337","DOI":"10.1021\/acs.jmedchem.2c00065","volume":"65","author":"GE Mudd","year":"2022","unstructured":"Mudd GE, Scott H, Chen L, van Rietschoten K, Ivanova-Berndt G, Dzionek K, et al. Discovery of BT8009: a nectin-4 targeting bicycle toxin conjugate for the treatment of cancer. J Med Chem. 2022;65(21):14337\u201347. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00065","journal-title":"J Med Chem"},{"key":"1361_CR16","doi-asserted-by":"publisher","unstructured":"Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot study of Nectin-4-Targeted PET imaging agent (68)Ga-FZ-NR-1 in Triple-Negative breast cancer from bench to First-in-Human. J Nucl Med. 2025;66(3):473-479. https:\/\/doi.org\/10.2967\/jnumed.124.269024","DOI":"10.2967\/jnumed.124.269024"},{"issue":"1","key":"1361_CR17","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1038\/s41598-020-61129-5","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, et al. Evaluation of radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer. Sci Rep. 2020;10(1):4179. https:\/\/doi.org\/10.1038\/s41598-020-61129-5","journal-title":"Sci Rep"},{"issue":"1","key":"1361_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7(1):88. https:\/\/doi.org\/10.1186\/s13550-017-0339-3","journal-title":"EJNMMI Res"},{"key":"1361_CR19","doi-asserted-by":"publisher","unstructured":"Bikirli F, Hilal N, Altinsoy, T\u00fcrkay T. Effective dose Estimation with IDAC and OLINDA for 18F-FDG and 68Ga-PSMA PET\/CT procedures. Health Phys. Published online August 29, 2025. (2025):10\u20131097. https:\/\/doi.org\/10.1097\/HP.0000000000002034","DOI":"10.1097\/HP.0000000000002034"},{"issue":"10","key":"1361_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Velikyan I, Garske-Rom\u00e1n U, S\u00f6rensen J, Eriksson B, Granberg D, et al . Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755\u20139. https:\/\/doi.org\/10.2967\/jnumed.113.120600","journal-title":"J Nucl Med"},{"issue":"17","key":"1361_CR21","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","volume":"29","author":"X Duan","year":"2023","unstructured":"Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, et al. First-in-Human study of the radioligand 68Ga-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma. Clin Cancer Res. 2023;29(17):3395\u2013407. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0609","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1361_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","volume":"20","author":"F Shao","year":"2022","unstructured":"Shao F, Pan Z, Long Y, Zhu Z, Wang K, Ji H, et al. Nectin-4-targeted Immuno SPECT\/CT imaging and photothermal therapy of triple-negative breast cancer. J Nanobiotechnol. 2022;20(1):243. https:\/\/doi.org\/10.1186\/s12951-022-01444-3","journal-title":"J Nanobiotechnol"},{"key":"1361_CR23","doi-asserted-by":"publisher","unstructured":"Jiang C, Wei M, Li P, Hu S, Xu X, Li J, et al. A pilot study of nectin-4-targeted radioligand [68Ga] Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG. Eur J Nucl Med Mol Imaging 2025:1\u201313. Published online October 24, 2025. https:\/\/doi.org\/10.1007\/s00259-025-07609-0","DOI":"10.1007\/s00259-025-07609-0"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01361-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:59:52Z","timestamp":1770119992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-025-01361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01361-0","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committee, the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards. This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center and complied with its ethical regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"21"}}